Results 191 to 200 of about 469,928 (258)

A Novel IDO1/NE Dual Inhibitor, IMM‐H018 Prevents the Primary and Secondary Sepsis and Ameliorates the Kidney Injury Through Inhibiting the Cytokine Storm and Microthrombosis, and Reversing Immunosuppression

Advanced Science, EarlyView.
IMM‐H018, a dual IDO1/NE inhibitor, demonstrates potent therapeutic efficacy in sepsis by simultaneously targeting excessive inflammation and immune dysfunction. It prevents both primary and secondary sepsis through anti‐inflammatory, immune‐restoring, and renoprotective mechanisms, reducing organ damage, improving immune homeostasis, preserving kidney
Yi Zhou, Xiaodi Zhao, Xiaochen Pan, Zhiling Ma, Huaqing Cui, Hui Wen, Peng Wang, Xiufeng Liao, Kejie Qin, Yuchen Wang, Li Sheng, Sen Zhang   +11 more
wiley   +1 more source

Optimized Lipid Nanoparticles with Tail‐Modified Ionizable Lipids for Safer mRNA Delivery

Advanced Science, EarlyView.
Systematic engineering of hydrophobic tail architecture in vitamin B5‐derived ionizable lipids establishes a comprehensive structure–activity relationship framework for mRNA delivery. Combined lipidtail and formulation optimization identifies TM1‐OPT3‐C, a lipid nanoparticle platform that improves efficacy–safety balance through efficient mRNA delivery,
Seo‐Hyeon Bae, Jisun Lee, Jae‐Hun Ahn, Hosam Choi, Huijeong Choi, Jungmin Kim, Minho Kang, Ho Rim Oh, So Hyun Park, Eun Young Oh, Sanghyuk Jeon, Yeeun Lee, Yu‐Sun Lee, Na‐Young Lee, Hee‐Jin Bae, Jina Kwak, Jooil Kim, Nakyung Lee, Beomsun Kang, Ji‐Hye Kim, Eunsaem Song, Daesub Song, Hyunho Yoon, Sang‐Myeong Lee, Hyewon Youn, Kiyoun Lee, Byeong‐Cheol Kang, Jae‐Hwan Nam   +27 more
wiley   +1 more source

Targeted β‐Glucan‐Veiled Oral Apremilast Nanotherapy Modulates Key Dysbiosis‐Associated Gut Microbiota and Alleviates Ulcerative Colitis‐Associated Anxiety, Depression, and Neuropsychiatric Behaviors

Advanced Science, EarlyView.
This study introduces β‐glucan‐shielded apremilast laden nanomicelles that withstand gastrointestinal degradation, selectively accumulate in inflamed colon tissue, and modulate the microbiota–gut–brain axis. The formulation restores barrier integrity, reduces systemic and neuroinflammation, and improves anxiety‐ and depression‐like behaviors in colitis
Chandrashekhar Jori, Ahmed Shaney Rehman, Taruna Lamba, Anas Ahmad, Jattin Kumar, Aneesh Ali, Ajesh Joshi, Ashraf Ali, Suhel Parvez, Javed N. Agrewala, Rehan Khan   +10 more
wiley   +1 more source

Probiotic‐Derived Vesicles Rectally Delivered via Thermo‐Gelling Copolymer Promote Mucosal Healing and Reduce Inflammation in Ulcerative Colitis

Advanced Science, EarlyView.
A thermo‐responsive rectal delivery platform integrating probiotic‐derived extracellular vesicles within a hyaluronic acid‐based copolymer enables localized and sustained therapy for ulcerative colitis. The formulation effectively suppresses inflammation, promotes macrophage polarization toward a regenerative phenotype, restores epithelial barrier ...
Ayushi Mairal, Ubaid Tariq, Shreya Mehrotra, Saravanan Matheshwaran, Jan Marsal, Ashok Kumar   +5 more
wiley   +1 more source

Membrane‐Active Peptide Protects Against Inflammation by Targeting NLRP3 Activation at the Trans‐Golgi Network

Advanced Science, EarlyView.
The membrane‐active peptide Pep19‐2.5 reduces harmful inflammation by blocking activation of the NLRP3 inflammasome at trans‐Golgi network membranes. By targeting key membrane interactions, Pep19‐2.5 suppresses inflammatory IL‐1β production and alleviates allergic airway inflammation in mice, leading to reduced immune cell infiltration and improved ...
Jonas Engelhardt, Nico Kirsch, Aileen Kerfin, Lars P. Lunding, Dominic Ferber, Hannes Buthmann, Ilka Schreier, Carlotta Bosio, Ann‐Kathrin Dobbelstein, Anna Klawonn, Rebecca C. Coll, Lena Bauernhofer, Sandro Keller, Matthias Geyer, Michael Wegmann, Andra B. Schromm, Günther Weindl   +16 more
wiley   +1 more source

Interleukin-6 receptor antibodies (tocilizumab) in acute myocardial infarction with intermediate to high risk of cardiogenic shock development (DOBERMANN-T): study protocol for a double-blinded, placebo-controlled, single-center, randomized clinical trial. [PDF]

Trials
Kunkel JB, Holle SLD, Hassager C, Pecini R, Wiberg S, Palm P, Holmvang L, Bang LE, Kjærgaard J, Thomsen JH, Engstrøm T, Møller JE, Lønborg JT, Frydland M, Søholm H.   +14 more
europepmc   +1 more source

PEAR1 Promotes Glucose Metabolism Reprogramming in Sepsis‐Associated Acute Lung Injury via AARS1‐Mediated HIF‐1α Lactylation

Advanced Science, EarlyView.
This study revealed that a PEAR1/HIF‐1α/ glycolysis/lactate/H3K18la positive feedback loop in PMVECs that drives the development of S‐ALI. Mechanistically, PEAR1 mediates the binding of HIF‐1α to AARS1, leading to the lactylation of HIF‐1α, the primary lactylation site of which is K172.
Shuai Li, Zongqing Lu, Pu Fang, Qingqing Pang, Xianghui Wu, Bo Wang, Min Liang, Jingjing Pan, Haobo Kong, Haijian Cai, Juanjuan Li, Jiaying Kang, Dongsheng Wang, Dunling Xia, Mengmeng Xu, Qinghai You   +15 more
wiley   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Therapeutic Targeting of the Interleukin-6 Receptor

Annual Review of Pharmacology and Toxicology, 2012
Interleukin (IL)-6 is a typical cytokine featuring redundancy and pleiotropic activity. It contributes to host defense against pathogens, but dysregulation of IL-6 production plays a significant pathological role in various autoimmune and inflammatory diseases.
, Masashi Narazaki, Tadamitsu Kishimoto   +2 more
exaly   +3 more sources